Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.
The study, presented at the American Society of Retina Specialists annual meeting by Paul Hahn, MD, PhD, FASRS, a retina specialist at NJRetina, compared intravitreal pegcetacoplan (PEG) vs. avacincaptad pegol (ACP) for the treatment of geographic atrophy (GA). Using anchored matching-adjusted indirect comparisons, researchers evaluated the decrease in GA lesion growth over a 24-month period in patients from phase 3